Company: APM
Filing Date: 2025-11-17
Form Type: F-1
Source: 0001213900-25-111548
Chunk: 99

Company: Aptorum Group Ltd
Filing Date: 2025-11-17
Form: F-1
Chunk 99
---
.S. GAAP. We have taken actions to remediate the abovementioned material weakness:

| ● | provide trainings to staff regarding to the preparation of financial                         
 statements in compliance with generally accepted accounting principles in the United States; |

| ● | change to a new and well-established accounting system to enhance 
 effectiveness and financial and system control;                   |

| ● | establish clear roles and responsibilities for accounting and           
 financial reporting staff to address finance and accounting issues; and |

| ● | continue to monitor the improvement on internal control over 
 financial reporting.                                         |

However, since we are still in the process of replenishing and building up a qualified finance and accounting team with sufficient dedicated resources, our management assessed that the deficiency related to the lack of dedicated resources to take responsibility for the finance and accounting functions and the preparation of financial statements in compliance with generally accepted accounting principles in the United States, or U.S. GAAP, still existed as of December 31, 2021. We cannot assure you that we will not identify additional material weaknesses or significant deficiencies in the future. Our management concluded that our internal controls over financial reporting were not effective as of December 31, 2021. Investors may lose confidence in our operating results, the price of the Aptorum Class A ordinary shares could decline and we may be subject to litigation or regulatory enforcement actions. In addition, if we are unable to meet the requirements of Section 404 of the Sarbanes-Oxley Act, the Aptorum Class A ordinary shares may not be able to remain listed on the Nasdaq Capital Market. 54 We may market our products, if approved, globally; if we do, we will be subject to the risk of doing business internationally. We operate and expect to operate in various countries, and we may not be able to market our products in, or develop new products successfully for, these markets. We may also encounter other risks of doing business internationally including but not limited to:

| ● | unexpected changes in, or impositions of, legislative or regulatory 
 requirements;                                                       |

| ● | efforts to develop an international sales, marketing and distribution                                                            
 organization may increase our expenses, divert our management’s attention from the acquisition or development of drug candidates 
 or cause us to forgo profitable licensing opportunities in these geographies;                                                    |

| ● | the occurrence of economic weakness, including inflation or 
 political instability;                                      |

| ● | the effects of applicable non-U.S. tax structures and potentially 
 adverse tax consequences;                                         |

| ● | differences